

Alzheimer's disease Global Market Analysis 2019 by Causes, Treatment, Symptoms, Stages and more...

A new market study, titled "Alzheimer's disease - Competitive Landscape and Market, Market Access Potential, Pricing, Pipeline Analysis 2019", has Been Published

PUNE, MAHARASTRA, INDIA, July 31, 2019 /EINPresswire.com/ -- [Alzheimer's disease Market](#)

Alzheimer's disease is the most common cause of dementia and increases in prevalence exponentially with age, with trends in the United States likely to worsen in ensuing decades. The economic burden of Alzheimer's disease is quite high including direct and indirect costs. Indirect costs are the most important costs in early and community-dwelling AD patients. Direct costs increase when the disorder progresses, and the patient is institutionalized, or a formal caregiver is required.

Opportunities:

In AD, the prevalence rate doubles every 5 years and various epidemiological studies have shown the exponential growth of prevalence rate with age, starting from around 1.5-2.5% in the 65-69-year bracket, reaching almost 40% in the 90-94 year age group.^{1,2} In addition, according to the World Health Organization (WHO) the proportion of people over 65 years is set to increase from 6.8% in 2000 to 16.2% by 2050. Consequently, the prevalence of dementia in 2005 (24 million) is expected to rise to 81 million by 2040, assuming no changes in incidence, mortality and current preventive or curative treatments for these disorders.

Request Free Sample Report at <https://www.wiseguyreports.com/sample-request/3640366-alzheimer-s-disease-competitive-landscape-and-market-market>

Scope of the report:

Adroit Healthcare Sciences "Alzheimer's disease - Competitive Landscape and Market, Market Access Potential, Pricing, Pipeline Analysis 2019" contains:

1. Report has covered the current treatment landscape, detailed description of the drugs, pricing and market access aspects
2. The current report contains detailed description, mechanism of action, technology, collaborations of the pipeline products. The report contains detailed description based on different phases, types and method of administration
3. The report contains pipeline products that are in the various stages of the development including Phase 3, Phase 2, Phase 1, preclinical and discovery stage
4. The report contains dormant and discontinued products

Why to buy:

The report provides a comprehensive overview of the current treatment landscape, unmet needs and expectations from the future therapies.

The report helps our clients in making key business decisions with respect to investment

With a comprehensive report contains the different products and companies involved, it helps in identifying the commercial opportunities

Table of Content:

Disease Overview
Epidemiology
Current Treatment landscape
Unmet needs
Currently approved products

- Axura
- Ebixa
- Exelon
- Memantine Merz
- Prometax
- Rivastigmine 1 A Pharma
- Rivastigmine Hexal
- Rivastigmine SandozFrance : HTA analysis

Germany: HTA analysis
United Kingdom: HTA analysis
Italy: HTA analysis
United States: HTA analysis

An Overview of Pipeline
Therapeutics under Development by companies
Late stage products
Mid stage products
Early stage products
Comparative Analysis
Therapeutic Assessment
Assessment by Phase
Dormant Products
Discontinued Products
Appendix
Methodology
About Adroit Healthcare Services
Contact Us
Disclaimer

View Detailed Report at <https://www.wiseguyreports.com/reports/3640366-alzheimer-s-disease-competitive-landscape-and-market-market>

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349 (US), +44 208 133 9349 (UK)
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.